TREM2 variants have been linked to a higher likelihood of developing late-onset AD and may impact how individuals respond to anti-inflammatory treatments (Wyss-Coray and Rogers, 2012; Guerreiro et al., 2013; Van Dongen and Van Gool, 2004). The gene discussed is TREM2; the disease is Alzheimer disease.